Fig. 7
MYC-induced activation of oncogenic pathways in TICs. a qRT-PCR of genes associated to MYC-bound M2 de novo enhancers in IMEC-MYC-PIK3CAH1047R and 1° and 2° xenograft tumors cells, normalized on GAPDH. Data are means ± SEM (n = 3) (**P < 0.01, ***P < 0.001; Student’s t-test). b ChIP-qPCR assessing H3K27ac and H3K4me1 deposition at the MYC-bound M2 de novo enhancer regions in IMEC-MYC-PIK3CAH1047R and XD cells. Data are means ± SEM (n = 3). c Average gene expression values of MYC direct target signature in breast cancer samples of the meta-data set stratified according to molecular subtype. Data are shown as mean ± standard error of the mean (SEM) (P < 0.0001; unpaired ttest). d Gene expression levels of MYC direct target genes (upper heatmap) and of basal-specific enhancer associated genes (MYC un-bound; lower heatmap) in breast cancer samples of the meta-data set stratified according to molecular subtype. e Kaplan−Meier analysis representing the probability of metastasis-free survival in 751 basal-like breast cancer patients from the meta-data set stratified according to high or low MYC direct target signature score
